Beijing Feiruida Medical Technology Co., Ltd.

Primary objective: To demonstrate that the sensitivity of perfluoropropane microbubble injection contrast-enhanced ultrasound (CEUS) imaging for differential diagnosis of benign and malignant focal liver lesions (FLL) is non-inferior to SonoVue®. Secondary objectives: To compare the ability of perfluoropropane microbubble injection and SonoVue® to provide more diagnostic information for the diagnosis of multiple FLLs; To compare the specificity and accuracy of perfluoropropane microbubble injection and SonoVue® for differential diagnosis of benign and malignant FLLs; To compare the safety of perfluoropropane microbubble injection and SonoVue®;

Primary purpose: In healthy volunteers, to evaluate the pharmacokinetic characteristics of FRD001 ultrasound contrast agent by monitoring the kinetics of perfluoropropane after intravenous injection of different doses (6 μl/kg, 12 μl/kg, 18 μl/kg) of FRD001 contrast agent Secondary purpose: In healthy volunteers, to evaluate the safety of FRD001 ultrasound contrast agent In healthy volunteers, to evaluate the ultrasound enhancement characteristics of FRD001 in the liver